Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Medical Research and Opinion

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/03007995.2016.1261817PMID 27852119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives

  2016cited by this paper
• Trends in Height of Japanese According to The National Health and Nutrition Survey in Japan

  2015cited by this paper
• Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5

  2015cited by this paper
• Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.

  2015cited by this paper
• Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

  2015cited by this paper
• β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians

  2015cited by this paper
• HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

  2014cited by this paper
• HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

  2014cited by this paper
• Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

  2014cited by this paper
• Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

  2014cited by this paper
• Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin

  2014cited by this paper
• Differences in the HbA1c‐lowering efficacy of glucagon‐like peptide‐1 analogues between Asians and non‐Asians: a systematic review and meta‐analysis

  2014cited by this paper
• Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

  2014cited by this paper
• A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

  2014cited by this paper
• Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

  2013cited by this paper
• Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

  2012cited by this paper
• Insulin‐secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non‐obese Japanese patients

  2011cited by this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

  2009cited by this paper
• Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes.

  2004cited by this paper

• Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) – a systematic review and meta-analysis

  2025cites this paper
• Computational assessment of the dimeric incretin GLP-1cpGLP-1 reveals the structural bases for its activity.

  2025cites this paper
• Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis

  2024cites this paper
• Optimizing expression, purification, structural and functional assessments of a novel dimeric incretin (GLP-1cpGLP-1).

  2023cites this paper
• Prefilled Dual Chamber Devices (DCDs) - Promising High-quality and Convenient Drug Delivery System.

  2021cites this paper
• An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes

  2020cites this paper
• Albiglutide for the management of type 2 diabetes

  2018cites this paper
• GLP-1 receptor agonists, carotid atherosclerosis and retinopathy

  2017cites this paper